Why the Ecofibre (ASX:EOF) share price is surging 30% higher this week

The hemp company's shares have been on fire lately…

| More on:
A drawing of a rocket follows a chart up, indicating share price lift

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ecofibre Ltd (ASX: EOF) share price has continued its impressive run today following an interim sales update.

During early afternoon trade, the hemp company's shares are fetching for $1.15, up 6.98%. This brings Ecofibre shares to a gain of around 30% over the last 4 trading days.

How is Ecofibre performing?

Investors are snapping up Ecofibre shares in light of the company's impressive sales figures for its Ananda Professional business.

Ecofibre's Ananda Health division is the number one provider of hemp-derived CBD for retail pharmacies in the United States. The business produces nutraceutical products, topical creams and ointments. There is even a CBD oil specifically for pets such as dogs and cats.

In its announcement, Ecofibre advised that its Ananda Professional CBD products have recorded their highest revenues since September 2020. The strong result has seen the business achieved sales of around $800,000 for the month of May. September 2020 sales attained roughly $900,000.

Management noted that while the sales rebound is positive, monthly results may fluctuate in the short term.

Ecofibre CEO, Eric Wang touched on the company's progress saying:

This result reflects a combination of trading conditions improving in our core independent pharmacy channel, ongoing investment in new products and direct engagement to support our pharmacy partners.

As we enter a post-COVID environment, we are beginning to see many of our pharmacy partners begin to return to normal operations. Whilst there is still a lot of focus on COVID related activities such as vaccines, it is pleasing to see signs of recovery in our core channel.

Additionally, sales of the new Ananda Professional Chewable products and Women's Health range have been encouraging. We also launched Ananda Professional's new direct-to- consumer e-commerce portal with 70 pharmacies in early May, and the business is now focused on building momentum through positive early-adopter experiences.

Ecofibre share price snapshot

While today's update has lifted Ecofibre shares even further, yearly share price performance has not been so kind to investors. The company's share price has fallen more than 50% from the past 12 months and is down almost 40% year-to-date.

Ecofibre has a market capitalisation of approximately $397 million, with approximately 341 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A doctor shrugs and holds his hands out.
Healthcare Shares

Down 36% in 2025, should you buy CSL shares today?

A leading investment expert offers his outlook for CSL’s beaten-down share price.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Why did Macquarie just downgrade CSL shares?

The broker has taken an axe to its valuation of this biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which drug company could pile on almost 30% in gains according to RBC Capital?

This drug company has plenty of irons in the fire, RBC Capital Markets says.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

This ASX 200 stock is charging higher on FDA approval news

This stock is avoiding the market weakness on Monday. Let's find out why.

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Key Canadian approval sends 10-bagger biotech's shares higher

This 10-bagger company has just released more good news, with a breakthrough in the Canadian market.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This biotech has lodged a key submission with US regulators

This company has lodged a key submission which will pave the way for sales of its heart failure software in…

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Let’s look at what experts are expecting from the healthcare giant in 2026.

Read more »

medical doctor performing surgery using surgical instruments
Healthcare Shares

Biotech company implants heart device in world first

This biotech company has implanted a heart device as part of a clinical trial looking to open up new markets.

Read more »